Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

First-line Ribociclib-AI Combo Associated with Better Symptom-Related QOL Vs Abemaciclib-AI in HR+/HER2− Advanced Breast Cancer

June 6, 2022
By Ryan McDonald
Article
Conference|ASCO Annual Meeting: Breast Cancer

Results of a matching-adjusted indirect comparison study showed that patients with HR-positive/HER2–negative advanced breast cancer treated with ribociclib and an aromatase inhibitor were more likely to have better symptom-related quality of life than patients who received abemaciclib and an aromatase inhibitor.

Quality of life outcomes were better in patients with HR-positive/HER2–negative advanced breast cancer when they were treated with ribociclib (Kisqali) and an aromatase inhibitor versus abemaciclib (Verzenio) and an aromatase inhibitor, according to findings from a matching-adjusted indirect comparison study.

The findings, which were presented during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, also showed that the time to first symptom deterioration (TTSD) significantly favored the ribociclib-containing treatment regimen.

“Cyclin-dependent kinases 4 and 6 inhibitors plus endocrine therapy are standards of care in the first-line treatment of patients with hormone receptor-positive, human epidermal growth factor receptor-negative advanced breast cancer,” the study authors wrote in a poster demonstrating the findings. “A statistically significant overall survival benefit with first-line ribociclib plus aromatase inhibitor was recently reported for MONALEESA-2; final [overall survival] results for the MONARCH 3 trial of first-line abemaciclib and aromatase inhibitor are pending.”

The CDK4/6 inhibitor drug class, which both abemaciclib and ribociclib belong to, is associated with various safety profiles. The problem is that many adverse events, even mild, may greatly impact a patient’s quality of life. The study authors noted that results from a previous survey of patients, advocates, nurses and oncologists identified that certain adverse effects — such as diarrhea and appetite loss —that occurred in patients treated with CDK4/6 inhibitors were moderate to severe in nature.

Moreover, the investigators wrote that patient reported outcomes are helpful but head-to-head studies are lacking. As a result, the study authors conducted a matched-adjusted indirect comparison analysis of the patients enrolled into the MONALEESA-2 and MONARCH 3 trials. Quality of life was measured using two questionnaires — the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and BR23. The QLQ-C30 consists of patient reported outcomes on the individuals physical, social, role, cognitive and emotional symptom burden. As for BR23, it assesses questions related to a patient’s side effects, body image and sexual functioning.

The median duration of follow-up for quality of life data was 26.73 months in the MONARCH 3 trial and 79.7 months in the MONALEESA-2 trial.

The findings showed that TTSD in functional and symptomatic scales significantly favored treatment with ribociclib. However, there were no significant differences in any of the functional domains.

In particular, TTSD was significantly better in terms of appetite loss (HR = 0.46; 95% CI, 0.27-0.81), diarrhea (HR = 0.42; 95% CI, 0.23-0.79), fatigue (HR = 0.63; 95% CI, 0.41-0.96) and arm symptoms (HR = 0.49; 95% CI, 0.30-0.79) in those who received the ribociclib-containing regimen.

“Interpretation of these results is limited to the subset of patients in (MONALEESA-2) who were matched to patients in (MONARCH 3),” the authors concluded.

Reference

Rodriguez C, Kaufman JL, Laubach J, et. al. Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/human epidermal growth factor receptor–negative (HR+/HER2−) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC). J Clin Oncol. 2022; 40 (suppl_16):1015. doi:10.1200/JCO.2022.40.16_suppl.1015

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer

Roman Fabbricatore
July 24th 2025
Article

A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Improved Outcomes With Nivolumab May Be Associated With CD163+ Macrophages in Metastatic RCC

Improved Outcomes With Nivolumab May Be Associated With CD163+ Macrophages in Metastatic RCC

Ashley Chan
July 21st 2025
Article

New research suggests high levels of CD163-positive tumor-associated macrophages may significantly improve nivolumab efficacy in metastatic RCC.


Neoantigen Vaccines Are Leading to a Personalized Frontier in RCC Immunotherapy

Neoantigen Vaccines Are Leading to a Personalized Frontier in RCC Immunotherapy

Ashling Wahner
July 20th 2025
Article

David A. Braun, MD, PhD, discusses how neoantigen vaccines are redefining RCC treatment, with the potential to activate potent, lasting T-cell activity.

Related Content

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer

Roman Fabbricatore
July 24th 2025
Article

A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Improved Outcomes With Nivolumab May Be Associated With CD163+ Macrophages in Metastatic RCC

Improved Outcomes With Nivolumab May Be Associated With CD163+ Macrophages in Metastatic RCC

Ashley Chan
July 21st 2025
Article

New research suggests high levels of CD163-positive tumor-associated macrophages may significantly improve nivolumab efficacy in metastatic RCC.


Neoantigen Vaccines Are Leading to a Personalized Frontier in RCC Immunotherapy

Neoantigen Vaccines Are Leading to a Personalized Frontier in RCC Immunotherapy

Ashling Wahner
July 20th 2025
Article

David A. Braun, MD, PhD, discusses how neoantigen vaccines are redefining RCC treatment, with the potential to activate potent, lasting T-cell activity.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.